Cargando…

Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder

BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [(123)I]meta-iodo-benzyl-guanidine scintigraphy ([(123)I]MIBG) and olfactory testing— in comparison to [...

Descripción completa

Detalles Bibliográficos
Autores principales: Janzen, Annette, Vadasz, David, Booij, Jan, Luster, Markus, Librizzi, Damiano, Henrich, Martin T., Timmermann, Lars, Habibi, Mahboubeh, Sittig, Elisabeth, Mayer, Geert, Geibl, Fanni, Oertel, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535565/
https://www.ncbi.nlm.nih.gov/pubmed/35754288
http://dx.doi.org/10.3233/JPD-223201
Descripción
Sumario:BACKGROUND: Isolated rapid eye movement sleep behavior disorder (iRBD) is prodromal for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). OBJECTIVE: We investigated the use of cardiac [(123)I]meta-iodo-benzyl-guanidine scintigraphy ([(123)I]MIBG) and olfactory testing— in comparison to [(123)I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single photon emission computed tomography ([(123)I]FP-CIT-SPECT)— for identifying iRBD patients as prodromal phenotype of PD/DLB. METHODS: 37 RBD subjects underwent cardiac [(123)I]MIBG and brain [(123)I]FP-CIT-SPECT at baseline. Olfactory (Sniffin’ Sticks), cognitive and motor functions were tested annually for ∼4 years. RESULTS: 29/37 (78.4%) subjects had a pathological [(123)I]MIBG, of whom 86.2% (25/29) presented at least a moderate hyposmia at baseline (threshold/discrimination/identification-(TDI-)score ≤25). 20/37 (54.1%) subjects had a pathological [(123)I]FP-CIT-SPECT, always combined with a pathological [(123)I]MIBG. In subjects with pathological [(123)I]MIBG, olfactory function worsened (mainly due to threshold and discrimination subscores) from baseline to follow-up (p = 0.005). Olfaction was more impaired in subjects with pathological [(123)I]MIBG compared to those with normal [(123)I]MIBG at baseline (p = 0.001) and follow-up (p < 0.001). UPDRS-III scores increased in subjects with both pathological [(123)I]MIBG and [(123)I]FP-CIT-SPECT. In this group, seven subjects phenoconverted to PD, all— except for one— presented with at least moderate hyposmia at baseline. CONCLUSION: A combination of the biomarkers “pathological [(123)I]MIBG” and “hyposmia” likely identifies iRBD patients in an early prodromal stage of PD/DLB, i.e., before nigrostriatal degeneration is visualized. One-third of the subjects with pathological [(123)I]MIBG had a normal [(123)I]FP-CIT-SPECT. Noteworthy, in iRBD subjects with pathological [(123)I]MIBG, olfactory impairment is progressive independent of the [(123)I]FP-CIT-SPECT status.